Pain Therapeutics, Inc. Stock Nasdaq
Stocks
US69562K1007
Biotechnology & Medical Research
|
End-of-day quote
Nasdaq
|
||
| - USD | - |
|
| Market Cap | 42.03M 36.89M 34.68M 31.71M 59.25M 4.03B 59.69M 417M 161M 2.05B 158M 154M 6.66B | P/E 2026 * |
-0.97x | P/E 2027 * | -0.73x |
|---|---|---|---|---|---|
| Enterprise Value | 42.03M 36.89M 34.68M 31.71M 59.25M 4.03B 59.69M 417M 161M 2.05B 158M 154M 6.66B | EV / Sales 2026 * |
-
| EV / Sales 2027 * | - |
| Free-Float |
97.95% | Yield 2026 * |
-
| Yield 2027 * | - |
| Manager | Title | Age | Since |
|---|---|---|---|
Richard Barry
CEO | Chief Executive Officer | 67 | 2024-09-05 |
Eric Schoen
DFI | Director of Finance/CFO | 57 | 2018-09-30 |
Joseph Hulihan
CTO | Chief Tech/Sci/R&D Officer | 70 | 2025-08-06 |
| Director | Title | Age | Since |
|---|---|---|---|
Patrick Scannon
BRD | Director/Board Member | 78 | 2007-12-06 |
Richard Barry
CHM | Chairman | 67 | 2024-07-16 |
Claude Nicaise
CHM | Chairman | 74 | 2024-09-08 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -3.30% | +2.97% | +54.99% | +104.15% | 74.18B | |
| -0.02% | -3.73% | +34.34% | +75.10% | 59.55B | |
| +0.63% | -3.37% | -15.03% | +364.72% | 25.84B | |
| -0.24% | -0.19% | -1.28% | -4.50% | 24.73B | |
| -1.05% | +1.07% | +21.45% | -10.04% | 20.87B | |
| -1.70% | -4.15% | +147.82% | +325.69% | 15.32B | |
| +0.63% | -2.43% | +46.67% | +161.43% | 14.06B | |
| -2.22% | -8.41% | -20.83% | +745.31% | 13.12B | |
| +0.58% | -3.04% | +21.39% | +243.28% | 11.85B | |
| Average | -0.74% | -0.80% | +32.17% | +222.79% | 28.84B | |
| Weighted average by Cap. | -1.14% | -0.22% | +34.88% | +158.85% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | - | - |
| Net income | -43.76M -38.4M -36.1M -33.01M -61.68M -4.19B -62.13M -434M -168M -2.14B -164M -161M -6.93B | -60M -52.66M -49.5M -45.26M -84.57M -5.75B -85.2M -595M -231M -2.93B -225M -220M -9.5B |
| Net Debt | - | - |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Select your edition
All financial news and data tailored to specific country editions
